Labiotech.eu

News and Trends 6 Dec 2023

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]

December 6, 2023 - 6 minutesmins - By Willow Shah-Neville

More News! 4 Dec 2023

FDA CAR-T cell therapy warning: Are T cells malignant?

Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]

December 4, 2023 - 4 minutesmins - By Jules Adam

News and Trends 1 Dec 2023

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]

December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter

Podcast 1 Dec 2023

Ipsen drug gives hope for liver disease patients

On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […]

December 1, 2023

In Depth 30 Nov 2023

Could an Alzheimer’s vaccine make treatment more affordable?

Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]

November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter

Opinion 29 Nov 2023

Redefining drug development: the trailblazing evolution of the pharmaceutical industry

Drug discovery and development is a long, costly, and high-risk process that takes over 10 to 15 years with an average cost of over $1 to $2 billion for each new drug to be approved for clinical use. For any pharmaceutical company or academic institution, it is a big achievement to advance a drug candidate […]

November 29, 2023 - 9 minutesmins - By External Contributor

Best in Biotech 28 Nov 2023

Five companies shaping Texas’ growing biotech hubs

Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […]

November 28, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 27 Nov 2023

How are R&D Tax Incentives shaping Australia’s biotech future?

Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […]

November 27, 2023 - 5 minutesmins - By Jules Adam

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […]

November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter

Podcast 24 Nov 2023

Company exits stealth to launch molecular gates

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of Gate Bioscience. Gate Bioscience is a U.S.-based biotechnology company creating a new class of medicines called Molecular Gates. Founded in 2021, Gate is emerging from stealth with a novel scientific platform and $60 million in Series A funding […]

November 24, 2023

In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]

November 23, 2023 - 5 minutesmins - By Jules Adam

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

FDA CAR-T cell therapy warning: Are T cells malignant?

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

Ipsen drug gives hope for liver disease patients

Could an Alzheimer’s vaccine make treatment more affordable?

Redefining drug development: the trailblazing evolution of the pharmaceutical industry

Five companies shaping Texas’ growing biotech hubs

How are R&D Tax Incentives shaping Australia’s biotech future?

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Company exits stealth to launch molecular gates

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!